SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (1818)3/6/2018 5:30:58 PM
From: Miljenko Zuanic   of 1840
 
Thanks.

So, the best way is to develop drug for ultra-orphan indication, and priced accordingly, and than expand it toward 500K+ population. Why to go.
Isn't VRTX in CF doing exactly that?
Price of the cancer treatment is going to be be very complex in coming years, when IO/IO/... or any triple combination start to emerge from "targeted" (ultra-orphan) drugs.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News